The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer
Open Access
- 21 June 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (30) , 48265-48279
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Neus Martínez-Bosch1, Pedro Enrique Guerrero1, Mireia Moreno1, Anabel José2, 3, Mar Iglesias4, Jessica Munné-Collado4, Héctor Anta1, 5, Joan Gibert1, Carlos Alberto Orozco1, Judith Vinaixa1, Cristina Fillat2, 3, Francesc Viñals6, Pilar Navarro1 1IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain 2Biomedical Research Institute August Pi i Sunyer-IDIBAPS, Barcelona, Spain 3Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain 4Pathology Service, Hospital del Mar, Barcelona, Spain 5Institute for Research in, Biomedicine (IRB, Barcelona), Barcelona, Spain 6Catalan Institute of Oncology-IDIBELL, Barcelona University, Barcelona, Spain Correspondence to: Pilar Navarro, email: pnavarro@imim.es Keywords: sunitinib, pancreatic cancer, PDA, acinar carcinoma, fibrosis Received: January 14, 2016 Accepted: June 06, 2016 Published: June 21, 2016Keywords
This publication has 65 references indexed in Scilit:
- MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancerInternational Journal of Nanomedicine, 2014
- Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategiesWorld Journal of Gastroenterology, 2014
- Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic CancerPLOS ONE, 2012
- Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancerHPB, 2011
- Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.2009
- Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell CarcinomaClinical Cancer Research, 2007
- Genetically Engineered Models Have Advantages over Xenografts for Preclinical StudiesCancer Research, 2006
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006
- A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of CancerJournal of Clinical Oncology, 2005
- Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessmentVeterinary Record, 1985